The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.
The VISTA-16 trial of varespladib , a secretory phospholipase A2 ( sPLA2 ) inhibitor , in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm . Despite these discouraging results , therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation .
Which enzyme is inhibited by Varespladib?
Which enzyme is inhibited by Varespladib ?
secretory phospholipase A2
secretory phospholipase A2